Illustrative image.
Mavyret
Glecaprevir And Pibrentasvir
$3815.00
50/20mg · 28 sachets
BrandBranded medicine· By Abbvie
Strength
Choose a pack
- Selected pack
Packs in this delivery
Test mode: no payment is taken. View cart
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
50/20mg
100/40MG
FDA boxed warningRisk of hepatitis b virus reactivation in patients coinfected with hcv and hbv
Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with MAVYRET. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated
Hepatitis B virus (HBV) reactivation has been reported, in some cases resulting in fulminant hepatitis, hepatic failure, and death.
About Mavyret
Overview
Mavyret contains glecaprevir and pibrentasvir, two direct-acting antiviral medicines. It treats acute or chronic hepatitis C caused by virus types 1–6 in adults and children aged 3 years and older who have no cirrhosis or have compensated cirrhosis, meaning the liver is scarred but still functioning. It is also used for certain previously treated patients with hepatitis C type 1. The two ingredients work against hepatitis C by blocking different proteins in the virus.
What it treats
- Acute or chronic hepatitis C infection caused by genotypes 1–6 in adults and children aged 3 years and older, without cirrhosis or with compensated cirrhosis (Child-Pugh A). - Genotype 1 hepatitis C infection in adults and children aged 3 years and older previously treated with an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.
Safety information
Side effects
The most commonly reported side effects are headache and fatigue, each affecting more than 10% of people receiving Mavyret. Serious risks include reactivation of hepatitis B and worsening liver function or liver failure, including fatal cases. Contact your doctor if you develop worsening liver problems. Liver failure has been reported mostly in people with cirrhosis and moderate or severe liver impairment before treatment. All patients should be tested for current or past hepatitis B infection before treatment. People with both hepatitis B and hepatitis C need monitoring for hepatitis B reactivation and liver inflammation during treatment and follow-up. Mavyret must be stopped if worsening liver function or liver failure develops.
FDA boxed warning
Risk of hepatitis b virus reactivation in patients coinfected with hcv and hbv
Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with MAVYRET. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated
Hepatitis B virus (HBV) reactivation has been reported, in some cases resulting in fulminant hepatitis, hepatic failure, and death.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
Do not take Mavyret if you have moderate or severe liver impairment (Child-Pugh B or C), or if you have ever had liver decompensation, meaning your liver could no longer function adequately. Do not take it with atazanavir or rifampin. Hepatitis B can reactivate during treatment. All patients should be tested for current or past hepatitis B infection before starting treatment. If you have both hepatitis B and hepatitis C, you need monitoring for hepatitis B reactivation and worsening liver inflammation during treatment and follow-up. Liver decompensation or failure, including fatal cases, has been reported, mostly in people with cirrhosis and moderate or severe liver impairment. Patients with advanced liver disease need monitoring for signs of worsening liver function. Mavyret must be stopped if liver decompensation or failure develops.
Interactions
Tell your doctor if you take carbamazepine, an efavirenz-containing medicine, or St. John’s wort. These can lower the levels of glecaprevir and pibrentasvir, and taking them with Mavyret is not recommended. Clearing hepatitis C may change liver function, which can affect how other medicines work. Your doctor may need to monitor blood clotting results (INR) or blood glucose more often and adjust certain other medicines. Ask your doctor to review your medicines and supplements for possible interactions before and during Mavyret treatment.
Using Mavyret
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label MAVYRET (GLECAPREVIR AND PIBRENTASVIR) TABLET, FILM COATED MAVYRET (GLECAPREVIR AND PIBRENTASVIR) PELLET [ABBVIE INC.] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Ziagen
Abacavir
By GSK
Tablets · from 60 per pack
Also for antivirals
Brand $767.00
Baraclude
Enetecavir
By Bristol Myers
Tablets · from 30 per pack
Also for antivirals
Brand from $1,203.00
Isenrtess
Raltegravir
By MSD
Tablets · from 60 per pack
Also for antivirals
Brand $1,398.00
STRIBILD
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate
By Gilead Sciences
Tablets · from 30 per pack
Also for antivirals
Brand $1,405.00